Drug Landscape ›
Topical Antibiotic ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 12
Most-reported reactions
Acne — 2 reports (16.67%) Retinal Detachment — 2 reports (16.67%) Application Site Burn — 1 report (8.33%) Chest Pain — 1 report (8.33%) Cough — 1 report (8.33%) Diarrhoea Haemorrhagic — 1 report (8.33%) Drug Ineffective — 1 report (8.33%) Intentional Product Misuse — 1 report (8.33%) Intraocular Pressure Increased — 1 report (8.33%) Nasopharyngitis — 1 report (8.33%)
Source database →
Topical Antibiotic in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Topical Antibiotic approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Topical Antibiotic in United States?
Hamilton Health Sciences Corporation is the originator. The local marketing authorisation holder may differ — check the official source linked above.